Bulletin
Investor Alert

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Deciphera Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 26, 2022, 5:17 p.m.

DCPH
/zigman2/quotes/203556943/composite

$

8.20

Change

-0.03 -0.36%

Volume

Volume 21,863

Quotes are delayed by 20 min

/zigman2/quotes/203556943/composite

Today's close

$ 8.42

$ 8.23

Change

-0.19 -2.26%

Day low

Day high

$8.16

$8.90

Open

52 week low

52 week high

$7.63

$52.43

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Deciphera Pharmaceuticals Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue ---25M42.09M
Cost of Goods Sold (COGS) incl. D&A 90,000150,000317,000-5.36M
COGS excluding D&A ----225,000
Depreciation & Amortization Expense 90,000150,000317,000830,0005.14M
Depreciation 90,000150,000317,000830,0005.14M
Amortization of Intangibles -----
Gross Income (90,000)(150,000)(317,000)-36.72M
20162017201820192020 5-year trend
SG&A Expense 25.75M50.79M103.78M224.9M307.91M
Research & Development 20.16M39.51M82.89M156.78M196.67M
Other SG&A 5.59M11.27M20.9M68.12M111.25M
Other Operating Expense -----
Unusual Expense -----
EBIT after Unusual Expense -----
Non Operating Income/Expense 4,000746,0004.33M8.54M4.7M
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense 106,00095,00084,00067,000-
Gross Interest Expense 106,00095,00084,00067,000-
Interest Capitalized -----
Pretax Income (25.94M)(50.28M)(99.85M)(192.26M)(266.49M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (25.94M)(50.28M)(99.85M)(192.26M)(266.49M)
Minority Interest Expense -----
Net Income (25.94M)(50.28M)(99.85M)(192.26M)(266.49M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (25.94M)(50.28M)(99.85M)(192.26M)(266.49M)
Preferred Dividends -----
Net Income Available to Common (25.94M)(50.28M)(99.85M)(192.26M)(266.49M)
EPS (Basic) (0.78)(2.99)(2.82)(4.48)(4.78)
Basic Shares Outstanding 33.05M16.79M35.39M42.87M55.78M
EPS (Diluted) (0.78)(2.99)(2.82)(4.48)(4.78)
Diluted Shares Outstanding 33.05M16.79M35.39M42.87M55.78M
EBITDA (25.75M)(50.79M)(103.78M)(199.9M)(266.05M)
Copyright 2022 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Trending Tickers
  • /zigman2/quotes/201786389/composite USA+0.11%
  • /zigman2/quotes/205971581/composite VIXM+1.50%
  • /zigman2/quotes/204412041/composite KMX+0.98%
  • /zigman2/quotes/205782082/composite IT-0.70%
  • /zigman2/quotes/200387963/composite LINK+1.77%
X
Powered by StockTwits
Link to MarketWatch's Slice.